Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Enhancing immunotherapies against solid tumors with TLR-switch receptor-armored T cells (TLR-T cells)

Project description

Advancing T cell therapy for solid tumours

Immunotherapy has reshaped how we treat cancer, but adoptive T cell therapies (ACTs) still face limited efficacy against solid tumours. This is due to the highly suppressive microenvironment that weakens T cell activity. With the support of the Marie Skłodowska-Curie Actions programme, the TLRT project aims to overcome that barrier by engineering T cells that can turn suppressive signals into activating ones. The idea is to reroute immune danger signals to boost T cell activity. By improving T cell strength and killing capacity, this approach could make ACTs far more effective across a broader range of solid tumours.

Objective

Immunotherapy, particularly adoptive T cell therapies (ACT), has revolutionized cancer treatment, providing significant benefits to patients with haematological malignancies. Despite these successes, their effectiveness against solid tumors remains limited. A major unaddressed obstacle in treating solid malignancies with ACT is the suppression of T cells within the tumor microenvironment (TME), which hampers their sustained activity against tumor cells. Thus, there is a critical need to optimize these therapies to be effective against a wider range of cancer types. One promising approach involves engineering adoptive T cells with switch receptors (SRs) that convert the detection of extracellular suppressive signals into intracellular T cell activation. Damage-associated molecular patterns (DAMPs) are endogenous ‘danger’ ligands and powerful innate immune agonists that signal through Toll-like receptors (TLRs) to various cell types, playing an essential role in mounting protective immunity. However, the potential to utilize these innate immune signals to empower therapeutic T cells remains unexplored. This research proposal aims to enhance ACT against solid tumors by leveraging innate immune signals to improve T cell function within the suppressive TME. Specifically, the goals are (1) to design innovative SRs that amplify TLR costimulatory signalling upon detecting TME immunosuppressive factors, and (2) to incorporate these SRs into T cells, evaluating their therapeutic potential in both TCR-T and CAR-T therapies using complementary murine and human tumor models. By harnessing innate inflammatory signals, the proposed strategy seeks to boost fitness, cytotoxicity, and resilience of infused T cells, enabling them to navigate and function more effectively within the immunosuppressive TME of solid tumors. The advancements from this research could be transformative for cancer treatment paradigms, offering new hope for a broader spectrum of cancer patients.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Net EU contribution
€ 202 125,12
Address
GESCHWISTER SCHOLL PLATZ 1
80539 Planegg
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data